A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Crohn Disease

ConditionCrohn Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAll India Institute of Medical Sciences

About this trial

Dysbiosis can be rectified by several methods: antibiotics, prebiotics, probiotics, dietary modulation, and fecal microbiota transplantation. There has been limited success with the isolated use of antibiotics and pre/probiotics in the treatment of IBD. Among the measures of dietary manipulation, the use of exclusive enteral nutrition (EEN) has shown superior, or at least equivalent, efficacy compared with steroids in pediatric CD. Although the results in adults are not as encouraging, recent cohort studies in patients with complicated CD have shown good success rates. Definite exclusion diets that exclude pro-inflammatory dietary constituents have also been tested with good clinical efficacy in patients with CD, who even failed treatment with anti-TNF agents. Various dietary approaches, inclusive of exclusive enteral nutrition, partial enteral nutrition, and Crohn's disease exclusion diet have been reported to be of benefit and are associated with changes in gut microbiome. Fecal microbiota transplantation (FMT) defined as the infusion of fecal suspension from a healthy individual into the gastrointestinal tract of an individual with GI disease carries a diverse population of microbiota and their metabolites and has been tested with varying efficacy in IBD. In general, FMT has shown good success rates in randomized control trials in patients with UC who failed conventional agents. Although limited small RCTs exist in CD, cohort studies have also shown good success rates. Therefore, the use of FMT in addition to standard medical therapy, is a concept that has not been previously explored and forms the basis for the present study. Therefore, a well-powered RCT is required to resolve the role of FMT in CD. In this study, patients will be recruited in four arms. Group A includes FMT+CDED+SMT, in Group B FMT+SMT+SHAM DIET, in Group C Sham FMT+CDED+SMT, in Group D Sham FMT+ Sham Diet+ SMT given. 168 patients will be recruited across 6 centers for around 3 years. Follow-up of the patient will be done at 0,2,6 and 10 weeks and 8 weekly up to 48 weeks.

Eligibility criteria

Qualifiers

Patients with treatment-naive Crohns disease accessible with ileocolonoscopy

Symptom onset of less than 12 months

Mild to moderate disease activity with endoscopically active disease

CDAI of greater than 150 and less than 450

Disqualifiers

Patients with severe disease (CDAI greater than 450, SES-CD greater than 16) or requiring hospitalization

Patients who have been received on corticosteroids, immunosuppressants (azathioprine/ 6- mercaptoprine/methotrexate) for greater than 2 weeks

Biologicals or small molecule exposure

Stricturing (non-passable stricture), fistulising phenotype or perianal fistula/abscess

Trial design

Treatments tested in this trial

  • Fecal Microbial Transplantation
  • Sham transplantation
  • Crohns disease exclusion diet
  • Sham diet

Treatment groups

168 Participants
are divided into 4 treatment groups

Sponsors and collaborators

All India Institute of Medical Sciences

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Collaborator

Dayanand Medical College and Hospital

Collaborator

Institute of Medical Sciences of the Banaras Hindu University, India

Collaborator

Lokmanya Tilak Municipal Medical College and Hospital

Collaborator

Lisie Hospital

Collaborator

Indraprastha Institute of Information Technology Delhi

Collaborator

Indian Council of Medical Research

Collaborator